Literature DB >> 8809955

Adenocarcinoma of the gastric antrum: does D2 total gastrectomy with splenectomy improve prognosis compared to D1 subtotal gastrectomy? A long-term survival analysis with emphasis on Lauren classification.

D Roukos1, A Schmidt-Mathiesen, A Encke.   

Abstract

AIMS: The purpose of this retrospective study was to evaluate whether a more radical resection, including total gastrectomy (TG), D2 lymphadenectomy and splenectomy, or subtotal gastrectomy (SG), improves the prognosis of patients with an adenocarcinoma located on the distal third of the stomach. PATIENTS AND METHODS: Seventy-four consecutive patients with an antral carcinoma underwent gastric resection. Forty-three had a TG and 31 an SG. D2 lymph node dissection was carried out in 70% of all patients (30/43) and 100% (21/21) of patients with curative resection in the TG group, whereas in the SG group the patients had only a standard D1 lymph node dissection. Splenectomy was carried out in 84% (36/43) of patients in the TG group, whereas in the SG group the spleen was preserved in all patients. Follow-up was complete for 100% of the patients, with a median follow-up time of 74 months. MAIN END-POINTS OF INTEREST: Overall survival rates, mortality and morbidity rates.
RESULTS: The postoperative 30-day mortality rate was 7% in the TG group and 3.2% in the SG group. The overall morbidity rate was increased from 19% after SG to 37% after TG. There was no microscopic evidence of involvement of proximal resection margins in any of 31 subtotal resected gastric specimens. Lymph node metastases to the splenic hilus (no. 10 nodes) or along the splenic artery (no. 11 nodes) were not found in any of 36 patients who underwent splenectomy and lymphadenectomy. The 5- or 10-year survival rates did not differ significantly between both groups. Analysis of survival showed no significant difference between the TG and SG groups when related to subgroups of patients with curative resection (UICC-RO resection), nodal status (pN), tumour depth (pT-category), tumour stage (pTNM), or Lauren classification (intestinal or diffuse type of carcinoma). The survival rates for patients with curative resection after 5 or 10 years were 58% in the TG group and 66% or 51% in SG group, respectively (P = 0.66).
CONCLUSION: Since D2 total gastrectomy carried an increased overall morbidity risk and did not improve survival in patients with intestinal or diffuse type carcinoma, it seems that with regard to luminal gastric resection, SG is the treatment of choice for carcinomas located in the distal third of the stomach. Whether extensive radical D2 lymphadenectomy should be routinely performed in addition to SG is still controversial.The spleen should be preserved in most cases.

Entities:  

Mesh:

Year:  1995        PMID: 8809955     DOI: 10.1016/s0960-7404(10)80045-3

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

Review 1.  Extended lymphadenectomy in gastric cancer: when, for whom and why.

Authors:  D H Roukos
Journal:  Ann R Coll Surg Engl       Date:  1998-01       Impact factor: 1.891

2.  Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Motoshi Miyagi; Takuya Imaizumi; Junya Kizaki; Kazuo Shirouzu
Journal:  World J Hepatol       Date:  2010-02-27

Review 3.  Does Total Gastrectomy Provide Better Outcomes than Distal Subtotal Gastrectomy for Distal Gastric Cancer? A Systematic Review and Meta-Analysis.

Authors:  Jin Qi; Peng Zhang; Yanan Wang; Hao Chen; Yumin Li
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

4.  Total versus subtotal gastrectomy for distal gastric cancer: meta-analysis of randomized clinical trials.

Authors:  Lingling Kong; Nianzhao Yang; Lianghui Shi; Guohai Zhao; Minghai Wang; Yisheng Zhang
Journal:  Onco Targets Ther       Date:  2016-11-07       Impact factor: 4.147

5.  Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer.

Authors:  Qinchuan Wang; Xiang Shu; Yong Dong; Jichun Zhou; Rongyue Teng; Jianguo Shen; Yongxia Chen; Mingjun Dong; Wenjun Zhang; Yasheng Huang; Shuduo Xie; Qun Wei; Wenhe Zhao; Wenjun Chen; Xiaoming Yuan; Xu Qi; Linbo Wang
Journal:  Oncotarget       Date:  2017-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.